吉西他滨联合伯尔定治疗晚期非小细胞肺癌60例临床观察  

Efficacy and toxicity analysis of gemcitabine plus carboplatin in the treatment of advanced non-small-cell lung cancer

作　　者：钱夕惠[1] 蔡玮宇[1] 

机构地区：[1]江苏省肿瘤医院,210009

出　　处：《中国现代药物应用》2008年第17期30-31,共2页Chinese Journal of Modern Drug Application

摘　　要：目的观察吉西他滨联合伯尔定治疗晚期非小细胞肺癌的疗效及毒副作用。方法吉西他滨1000mg/m2,第1天及第8天静脉滴注。伯尔定AUC=5,第1天静脉滴注。21d为一周期,连续二周期。结果完全缓解(CR):0例;部分缓解(PR):28例;无变化(NC):26例;进展(PD):6例。有效率46.7%。主要毒副作用为粒细胞减少,血小板减少,皮疹,恶心呕吐等,经对症处理能缓解,不影响治疗。结论吉西他滨联合伯尔定治疗晚期非小细胞肺癌能取得较好的疗效。患者对毒副作用能耐受。Objective To observe the efficacy and toxicity of gemcitabine plus Carboplatin in the treatment of advanced non-small-cell lung eaneer（NSCLC）. Method Among 60 NSCLC cases, 24 patients were untreated cases. 36 patients were recurrent cases. They were treated by gemcitabine 1000 mg/m2 , ivgtt, at dl and d8 respeatively. Carboplatin AUC = 5,ivgtt at d1 . Result the response rate （ CR ＋ P1R） was 46.7% ;CR： 0 cases, PR：28cases, NC ：26 cases ; PD 6 cases . the major toxicity included myelosuppression, rash, nausea and vomiting. Conclusions The regimen of gemcitabine combination with earboplatin is effective, safe and bell-tolerated in the treatment of NSCLC.

关 键 词：非小细胞肺癌 化疗 吉西他滨 伯尔定 

分 类 号：R734.2[医药卫生—肿瘤] R285.1[医药卫生—临床医学]